Pulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium

Rhea-AI Summary

Pulse Biosciences, Inc. (PLSE) will feature its CellFX Nanosecond Pulsed Field (nsPFA) technology in a podium presentation at the 29th Annual AF Symposium in Boston, Massachusetts. The presentation will focus on the preliminary findings from the Company’s CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study and will be presented by Prof. Petr Neužil and Dr. Vivek Reddy. The technology has shown promise in the treatment of atrial fibrillation, with positive feedback from the initial procedures.

HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a company with a primary focus on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field (nsPFA) technology for the treatment of atrial fibrillation, today announced that its nsPFA technology will be featured in a podium presentation at the 29^th Annual AF Symposium in Boston, Massachusetts, on February 2, 2024 at 10:00am ET.

The session will include a presentation on the latest developments in Nanosecond Pulsed Field (nsPFA) technology, specifically highlighting the preliminary findings from the Company’s CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study. Dr. Petr Neužil, Chief of Cardiology at Na Homolce Hospital, Prague and Dr. Vivek Reddy, Director of Cardiac Arrhythmia Services at Mount Sinai Hospital, New York will provide an overview of their experience with the CellFX nsPFA 360 Cardiac Catheter and discuss the potential clinical implications and impact on the treatment of atrial fibrillation.

"I look forward to presenting one of our initial cases with this promising technology at the AF Symposium and am honored to be part of the team to perform the first-in-human procedures with the CellFX nsPFA 360 Cardiac Catheter," said Dr. Vivek Reddy. "The circumferential footprint and flexible structure of the 360 nsPFA catheter has been extremely fast and versatile in these initial procedures, setting it apart from many other PFA catheters. We look forward to completing enrollment in this study to fully assess the safety and durability of this next generation PFA technology."

Presentation Details:
Session: Case Transmissions Session 4
Title: Nanosecond Pulsed Field Ablation for AF
Presenters: Prof. Petr Neužil and Dr. Vivek Reddy
Session Date and Time: February 2, 2024 from 10:00 am – 12:30 pm ET

About Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The Company’s proprietary CellFX Nanosecond Pulsed Field (nsPFA) technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where CellFX nsPFA could have a profound positive impact on healthcare for both patients and providers.

Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the effectiveness of the Company’s CellFX nsPFA technology and CellFX System to non-thermally clear cells while sparing adjacent non-cellular tissue, statements concerning the Company’s expected product development efforts, such as advancement of its CellFX nsPFA 360 Cardiac Catheter to treat atrial fibrillation, whether faster than current thermal ablation technologies or otherwise, statements concerning whether any clinical study will show that the Company’s novel nsPFA mechanism of action and catheter design will deliver fast and precise ablations in cardiac tissue, statements concerning market opportunities, customer adoption and future use of the CellFX System to address a range of conditions such as atrial fibrillation, statements concerning early clinical successes and whether they are predictive of the safety and efficacy of any medical device such as the CellFX nsPFA 360 Cardiac Catheter, Pulse Biosciences’ expectations, whether stated or implied, regarding whether the Company’s CellFX nsPFA technology will become a disruptive treatment option for treating atrial fibrillation or any other medical condition, and other future events. These statements are not historical facts but rather are based on Pulse Biosciences’ current expectations, estimates, and projections regarding Pulse Biosciences’ business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expects,” “intends,” “plans,” “projects,” “believes,” “estimates,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Pulse Biosciences’ control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Pulse Biosciences’ filings with the Securities and Exchange Commission. Pulse Biosciences undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240131411137/en/

Investor Contacts:

Pulse Biosciences

Kevin Danahy, President and CEO

510.241.1077

IR@pulsebiosciences.com

or

Gilmartin Group

Philip Trip Taylor

415.937.5406

philip@gilmartinir.com

Source: Pulse Biosciences, Inc.

FAQ

What is the primary focus of Pulse Biosciences, Inc. (PLSE)?

Pulse Biosciences, Inc. (PLSE) has a primary focus on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field (nsPFA) technology for the treatment of atrial fibrillation.

What will be featured in a podium presentation at the 29th Annual AF Symposium?

Pulse Biosciences, Inc.'s (PLSE) nsPFA technology will be featured in a podium presentation at the 29th Annual AF Symposium, focusing on the preliminary findings from the Company’s CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study.

Who will be presenting at the 29th Annual AF Symposium?

Prof. Petr Neužil and Dr. Vivek Reddy will be presenting at the 29th Annual AF Symposium, discussing the latest developments in Nanosecond Pulsed Field (nsPFA) technology and the potential clinical implications and impact on the treatment of atrial fibrillation.

What is the title of the presentation at the 29th Annual AF Symposium?

The title of the presentation at the 29th Annual AF Symposium is 'Nanosecond Pulsed Field Ablation for AF'.

When and where will the presentation take place?

The presentation will take place on February 2, 2024, from 10:00 am – 12:30 pm ET at the 29th Annual AF Symposium in Boston, Massachusetts.